118P Characterization and clinical impact of prior malignancy in rare driver-mutation NSCLC: A real-world cohort study

Conclusions:This study systematically identified the most relevant symptomatic AEs in patients with NSCLC receiving acasunlimab, pembrolizumab, and/or docetaxel, balancing comprehensive symptom capture with reduction of patient-reported burden.These findings support the targeted use of PROs to enhance benefit-risk evaluation and better inform clinical decision-making in lung cancer trials.Clinical trial identification: NCT05117242.